MLTX (MoonLake Immunotherapeutics) Short-Term Debt to Capital

Corporate company logo of MoonLake Immunotherapeutics (MLTX)

MoonLake Immunotherapeutics (MLTX) is developing scientific partnerships with global medical centers to create advanced inflammation therapies. The price indicator on the GURU.Markets platform chart shows a metric at 0.02. The company is developing unique nanobodies protected by patents against replication to compete with industry behemoths. Massive unmet demand for skin treatment will ensure a powerful influx of patients for the firm following trials.

Ratio of Short-Term Indebtedness to Capital: MoonLake Pharma (MLTX) for 04/28/2023 - 11/01/2026

Analytical breakdowns for MoonLake Immunotherapeutics

- stock quotes and analyst forecast:
Stock Price MoonLake Pharma|MLTX - Fair Value Consensus
- business market valuation indicators:
Market Capitalization MoonLake Immunotherapeutics AG|MLTX - Enterprise Value
- book capitalization information:
Net Assets per Single Share MoonLake Immunotherapeutics|MLTX - Accounting Value of Company|Market Value to Book Value Ratio moonlaketx.com|MLTX - Cumulative Company Assets
- company liabilities and liquidity data:
Total Debt to Capital MoonLake Immunotherapeutics|MLTX - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio MoonLake|MLTX - Aggregate Debt Obligations|Debt to Book Capitalization Ratio MoonLake Immunotherapeutics AG|MLTX - Company Long-Term Liabilities|Company Short-Term Debts MoonLake Immunotherapeutics|Quick Liquidity Indicator moonlaketx.com
- company profitability and valuation multiples indicators:
MLTX - Profit After Payment of Taxes
Fundamental valuation:MLTX MoonLake Pharma
Brand item of MoonLake Immunotherapeutics AG

For MoonLake Immunotherapeutics (MLTX), whose clinical trials are constrained by geopolitical instability and sanctions pressure, the ratio of short-term loans to equity serves as an indicator of financial resilience in the face of operational delays. This metric's dynamics reflect the daily proportion of short-term liabilities within the equity structure, allowing investors to promptly assess liquidity risk and the probability of a cash gap amid the slowing global rollout of the therapy.

Competitors of MoonLake Immunotherapeutics

Short-Term Debt to Capital ASND|MDGL (Madrigal Corp) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital CORT (Corcept Therapeutics)|Short-Term Debt to Capital rhythmtx.com RYTM|AKRO - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital MTSR (Metsera, Inc.)|Crinetics Pharma (CRNX) - Short-Term Debt to Equity|Short-Term Debt to Equity Ratio NewAmsterdam Pharma Corp|SLNO (Soleno Therapeutics) - Short-Term Debt to Capital|Short-Term Debt to Capital amicusrx.com|Short-Term Debt to Equity Ratio ETNB (89bio)|AGIO (Agios) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Structure Pharma GPCR|MDXG - Short-Term Debt to Equity Ratio|Rezolute, Inc. - Short-Term Debt to Capital|Current Liabilities to Capital lexpharma.com|MBX (MBX Biosciences) - Short-Term Debt to Equity Ratio|ALT: Short-Term Loans to Capital Ratio|AARD (Aardvark Therapeutics Corp) - Short-Term Debt to Capital|Short-Term Debt to Capital Sagimet Biosciences Inc|Short-Term Debt to Capital BIOA|Short-Term Debt to Equity BMEA (biomeafusion.com)|Short-Term Debt to Equity Quince Therapeutics, Inc. QNCX|Fractyl Health Inc. (GUTS) - Current Liabilities to Capital|VTVT - Short-Term Debt to Equity|ATPC: Short-Term Debt to Equity|PLUR: Short-Term Debt to Capital|SYBX - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Lipocine|Matinas BioPharma Holdings Inc. (MTNB) - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Spruce Biosciences (SPRB)|Short-Term Debt to Equity Ratio Galecto Corporation GLTO|Short-Term Debt to Equity Carmell Corporation CTCX|LUMO - Short-Term Debt to Equity Ratio|ONVO - Short-Term Debt to Equity|Current Liabilities to Capital Radius Recycling Inc.